Screener
Bristol-Myers Squibb BMY EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Bristol-Myers Squibb’s reported figures.
Based on trailing twelve months.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
FAQ
- What is Bristol-Myers Squibb's EBITDA margin?
- Bristol-Myers Squibb (BMY) reported EBITDA margin of 30.7% in Q2 2026.
- How has Bristol-Myers Squibb's EBITDA margin changed year-over-year?
- Bristol-Myers Squibb's EBITDA margin increased by 13.3% year-over-year, from 27.1% to 30.7%.
- What is the long-term trend for Bristol-Myers Squibb's EBITDA margin?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's EBITDA margin has grown at a 27.4% compound annual growth rate (CAGR), from 8.3% to 27.7%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Bristol-Myers Squibb's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude